Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TXMD message board posts where the ticker symbol TXMD has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TXMD SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001387131-18-003883 (34 Act)  Size: 5 MB
2018-08-13 001-00100
181010155
8-K  Documents Current report, items 1.01, 8.01, and 9.01
Acc-no: 0001193125-18-237291 (34 Act)  Size: 207 KB
2018-08-03 001-00100
18990528
424B2  Documents Prospectus [Rule 424(b)(2)]
Acc-no: 0001193125-18-236752 (33 Act)  Size: 1 MB
2018-08-02 333-207837
18989218
424B2  Documents Prospectus [Rule 424(b)(2)]
Acc-no: 0001193125-18-236743 (33 Act)  Size: 1 MB
2018-08-02 333-226452
18989084
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-18-233470 (33 Act)  Size: 1 MB
2018-07-31 333-207837
18982128
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-18-233467 (33 Act)  Size: 1 MB
2018-07-31 333-226452
18982121
S-3ASR  Documents Automatic shelf registration statement of securities of well-known seasoned issuers
Acc-no: 0001193125-18-233134 (33 Act)  Size: 535 KB
2018-07-31 333-226452
18981132
8-K  Documents Current report, items 2.02, 7.01, and 9.01
Acc-no: 0001387131-18-003402 (34 Act)  Size: 210 KB
2018-07-30 001-00100
18976025
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001387131-18-003401 (34 Act)  Size: 5 MB
2018-07-30 001-00100
18975998
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000080255-18-002777 (34 Act)  Size: 7 KB
2018-07-10 005-32384
More TXMD SEC Filings


Related news from
Fri, 10 Aug 2018
20:09:47 +0000
FDA Approves New Form Of Self-Administered Female Birth Control
On Friday, TherapeuticsMD Inc (NASDAQ: TXMD) announced FDA approval of the first-ever patient-controlled long-acting reversible vaginal birth control system. What Happened? The new birth control is the first of its kind and is likely to be classified as a “new chemical entity,” which would potentially grant TherapeuticsMD five years of patent exclusivity. “The U.S. contraceptive market is shifting toward long-acting solutions and we believe ANNOVERA represents an exciting new entrant for women and healthcare providers by providing the first woman-controlled, procedure-free, long-acting, reversible birth control product putting the woman in control of both her fertility and menstruation," said Dr. Brian Bernick, Co-Founder of TherapeuticsMD. What’s Next?
Fri, 10 Aug 2018
19:05:00 +0000
TherapeuticsMD Announces FDA Approval of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved ANNOVERA™ (segesterone acetate/ethinyl estradiol vaginal system), the first long-acting prescription birth control that is patient-controlled, procedure-free and reversible. The ANNOVERA contraceptive vaginal system is a small, soft flexible ring that prevents ovulation for an entire year (13 cycles) and can be inserted and removed by a woman at her discretion in repeated four-week cycles (remaining in place continuously for three weeks followed by removal for one week).
Thu, 09 Aug 2018
09:48:00 +0000
TherapeuticsMD Receives Bullish Note From Street on New Found Potential  
TherepeuticsMD (NYSE: TXMD), a commercial stage biopharma company focused on women’s health innovation, has seen massive stock price movement in the past few months as it goes through new developments in its service offering. Here we use TipRanks data to take a closer look at what Wall Street’s top analysts see in store for this surging stock over the next 12 months. The primary factor driving bullish sentiments from analysts is the company’s new product, Imvexxy.
Wed, 08 Aug 2018
12:03:01 +0000
See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
TherapeuticsMD Inc NASDAQ/NGS:TXMD
Mon, 06 Aug 2018
20:05:00 +0000
TherapeuticsMD Announces Closing of its Underwritten Public Offering and Concurrent Registered Direct Offering of Common Stock
TherapeuticsMD, Inc. (TXMD) today announced the closing of its previously announced $65 million underwritten public offering of common stock, at a price to the public of $5.10 per share, and concurrent $20 million registered direct offering of common stock to a strategic investor at a price of $5.10 per share. In connection with the underwritten public offering, TherapeuticsMD granted the underwriters an option to purchase up to an additional 1,911,764 shares of common stock at the public offering price less the underwriting discount, which option was exercised in full and closed. TherapeuticsMD received net proceeds from the offerings of approximately $90.0 million, after deducting underwriting discounts and offering expenses payable by TherapeuticsMD.
Mon, 06 Aug 2018
17:29:24 +0000
Edited Transcript of TXMD earnings conference call or presentation 30-Jul-18 12:30pm GMT
Q2 2018 TherapeuticsMD Inc Earnings Call
Thu, 02 Aug 2018
01:36:00 +0000
TherapeuticsMD Announces Pricing of Its Underwritten Public Offering and Concurrent Registered Direct Offering for Aggregate Gross Proceeds of $85 Million
TherapeuticsMD, Inc. (TXMD) today announced the pricing of its previously announced $65 million underwritten public offering of common stock at a price to the public of $5.10 per share. In addition, TherapeuticsMD has granted to the underwriters of the underwritten public offering an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional 1,911,764 shares of common stock. The gross proceeds to TherapeuticsMD from the offerings are expected to be approximately $85 million, before deducting underwriting discounts, commissions and other offering expenses payable by TherapeuticsMD, assuming no exercise of the underwriters’ option to purchase additional shares of common stock.
Tue, 31 Jul 2018
20:15:00 +0000
TherapeuticsMD Licenses Population Council’s Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that it has entered into an exclusive license agreement with the Population Council to commercialize its investigational segesterone acetate/ ethinyl estradiol one-year vaginal system for contraception in the United States (U.S.). The one-year vaginal contraceptive system is in the shape of a ring and combines a novel progestin, segesterone acetate (Nestorone®), with a widely used estrogen to prevent ovulation for an entire year (13 cycles). The New Drug Application (NDA) for the one-year vaginal contraceptive system is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date for the completion of the FDA’s review of the NDA of August 17, 2018.
Tue, 31 Jul 2018
20:13:00 +0000
Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership
Knight Therapeutics Inc. (GUD.TO) (“Knight”), a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that they have entered into a licensing agreement that grants Knight the rights to commercialize TX-004HR and TX-001HR in Canada and Israel. TX-004HR is TherapeuticsMD’s FDA-approved product, marketed as Imvexxy™ (estradiol vaginal inserts) in the U.S., for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
Tue, 31 Jul 2018
20:09:00 +0000
TherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering and Concurrent $20 Million Registered Direct Offering of Common Stock
TherapeuticsMD, Inc. (TXMD) today announced the launch of a $65 million underwritten public offering and a concurrent $20 million registered direct offering to a strategic investor of shares of its common stock. TherapeuticsMD also expects to grant the underwriters of the underwritten public offering a 30-day option to purchase up to an additional 15% of shares of common stock offered in the underwritten public offering. All of the shares in the offerings are to be sold by TherapeuticsMD.
Mon, 30 Jul 2018
10:30:00 +0000
TherapeuticsMD, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 30, 2018 / TherapeuticsMD, Inc. (NASDAQ: TXMD ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 30, 2018 at 8:30 AM Eastern Time. ...
Mon, 30 Jul 2018
10:15:00 +0000
TherapeuticsMD Announces Second Quarter 2018 Financial Results
-Imvexxy™ early experience program underway; national launch to commence August 6, 2018-
Wed, 25 Jul 2018
11:00:00 +0000
TherapeuticsMD to Report Second Quarter 2018 Financial Results on July 30, 2018
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that it will report its second quarter 2018 financial results on Monday, July 30, 2018, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.
Tue, 17 Jul 2018
11:30:00 +0000
Free Pre-Market Technical Recap on TherapeuticsMD and Three Additional Healthcare Stocks
LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on TXMD sign up now at www.wallstequities.com/registration. On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE AMER: PTN), TherapeuticsMD Inc. (NASDAQ: TXMD), and Zogenix Inc. (NASDAQ: ZGNX).
Thu, 07 Jun 2018
20:05:00 +0000
TherapeuticsMD Announces Draw Down of $75 Million Under Term Loan with MidCap Financial
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company has completed the first draw down of $75 million under its previously announced $200 million term loan facility with MidCap Financial, managed by Apollo Capital Management, L.P. The Company intends to use the proceeds from the financing to support the commercial launch of its recently approved product, Imvexxy™ (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women.
Thu, 07 Jun 2018
12:34:12 +0000
TherapeuticsMD (TXMD) Soars: Stock Adds 9.1% in Session
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Thu, 07 Jun 2018
11:00:00 +0000
TherapeuticsMD to Present at Goldman Sachs 39th Annual Global Healthcare Conference
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company will present at the Goldman Sachs 2018 Global Healthcare Conference being held on June 12-14, 2018 in Rancho Palos Verdes, CA.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This last year I have subscribed to two investment services, ValueForum and a well known income newsletter. ValueForum costs a little over 200 per year. The income newsletter costs about 400 per year. I am up 11% on investments made because I heard about them on ValueForum (of course, I do my own research on everything but the ideas came from ValueForum and there was always some discussion of the pros and cons of each investment on VF). I am down 8% on investments made because I heard about them from the income newsletter. I might also add that I often hear about breaking events immediately on ValueForum and a day or two later the same information is finally available from the newsletter. Hmmm...... which service is the better value?" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards